Pfizer Triples Down On CDK Inhibition In Breast, Other Cancers
CDK2, CDK4, CDK2/4/6 Drugs Now In Early Trials
Pfizer is looking to address breast cancer resistant to Ibrance and other CDK4/6 inhibitors, but sees potential paths to earlier lines of treatment and additional tumors.
You may also be interested in...
Arvinas, Pfizer Partner To Pursue Best-In-Class Breast Cancer Strategy
Pfizer agreed to pay up to $2.4bn to share development and commercialization costs for Arvinas’ estrogen receptor degrader, including in combination with Ibrance.
Keeping Track: US FDA Acts On 5 Novel Drugs: Approval For Fotivda, Pepaxto, Azstarys; CRLs For Defencath and Oral Paclitaxel
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker
ESMO: A Tale Of Two CDK 4/6 Inhibitors With monarchE Success and Failure For PALLAS
Two different outcomes for two different CD4/6 inhibitors – Eli Lilly’s Verzenio and Pfizer’s Ibrance – put the Lilly drug on track to be a new standard of care in high-risk early stage HR+, HER2-negative breast cancer. Novartis’s Kisqali could follow.